CENPC

Across TCGA pan-cancer cohorts, CENPC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CENPC data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CENPC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CENPC expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where CENPC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.925	0.596	.001	35	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	12	view →
UCEC	DFS	Tertile	II,III,IV	0.626	1.000	.039	4	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →
GBM	OS	Median	All	0.451	0.308	.046	2	view →
LSCC	OS	Tertile	All	0.901	0.724	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CENPC–CCRCC (DFS)

Open the CCRCC breakdown →